These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 29202563)
21. Quality of life after radio frequency ablation turbinate reduction (RFATR) among patients with rhinitis medicamentosa & withdrawal from decongestant topical spray abuse. Carmel Neiderman NN; Caspi I; Eisenberg N; Halevy N; Wengier A; Shpigel I; Ziv Baran T; Ringel B; Warshavsky A; Abergel A Am J Otolaryngol; 2023; 44(4):103842. PubMed ID: 36989755 [TBL] [Abstract][Full Text] [Related]
22. Increased frequency of rhinitis medicamentosa due to media advertising for nasal topical decongestants. Archontaki M; Symvoulakis EK; Hajiioannou JK; Stamou AK; Kastrinakis S; Bizaki AJ; Kyrmizakis DE B-ENT; 2009; 5(3):159-62. PubMed ID: 19902852 [TBL] [Abstract][Full Text] [Related]
23. [Ultrastructural changes in human nasal mucosa in rhinitis medicamentosa]. Knipping S; Holzhausen HJ; Riederer A; Bloching M HNO; 2006 Oct; 54(10):742-8. PubMed ID: 16477462 [TBL] [Abstract][Full Text] [Related]
24. Management of Rhinitis Medicamentosa: A Systematic Review. Zucker SM; Barton BM; McCoul ED Otolaryngol Head Neck Surg; 2019 Mar; 160(3):429-438. PubMed ID: 30325708 [TBL] [Abstract][Full Text] [Related]
25. Rhinitis medicamentosa: a nationwide survey of Canadian otolaryngologists. Fowler J; Chin CJ; Massoud E J Otolaryngol Head Neck Surg; 2019 Dec; 48(1):70. PubMed ID: 31818321 [TBL] [Abstract][Full Text] [Related]
26. Severe Rhinitis Medicamentosa Successfully Treated with Rhinolight® Endonasal UV Phototherapy. Carson P; Lyons M Ir Med J; 2019 Feb; 112(2):874. PubMed ID: 30875167 [TBL] [Abstract][Full Text] [Related]
27. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Graf P Allergy; 1997; 52(40 Suppl):28-34. PubMed ID: 9353558 [TBL] [Abstract][Full Text] [Related]
28. Topical glucocorticoid reduces the topical decongestant-induced histologic changes in an animal model nasal mucosa. Akpinar ME; Yigit O; Akakin D; Sarioz O; Ozkan N; Yildiz SD; Azizli E; Sehirli US Laryngoscope; 2012 Apr; 122(4):741-6. PubMed ID: 22374848 [TBL] [Abstract][Full Text] [Related]
29. Should Excess Topical Decongestant Use Raise a Red Flag? Rhinitis Medicamentosa and Opioid Use Disorder. Patel A; Levi JR; Brook CD Ann Otol Rhinol Laryngol; 2020 Feb; 129(2):164-169. PubMed ID: 31581795 [TBL] [Abstract][Full Text] [Related]
30. Mucosal changes in rhinitis medicamentosa. Lin CY; Cheng PH; Fang SY Ann Otol Rhinol Laryngol; 2004 Feb; 113(2):147-51. PubMed ID: 14994772 [TBL] [Abstract][Full Text] [Related]
31. Rhinitis medicamentosa: a review of causes and treatment. Graf P Treat Respir Med; 2005; 4(1):21-9. PubMed ID: 15725047 [TBL] [Abstract][Full Text] [Related]
39. Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling. Graf P; Juto JE Rhinology; 1995 Mar; 33(1):14-7. PubMed ID: 7540314 [TBL] [Abstract][Full Text] [Related]
40. One year follow-up of patients with rhinitis medicamentosa after vasoconstrictor withdrawal. Graf PM; Hallén H Am J Rhinol; 1997; 11(1):67-72. PubMed ID: 9065350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]